Cholesterol is an essential structural component of membranes that contributes to
membrane integrity and fluidity. Cholesterol homeostasis plays a critical role in the …

The pharmacological treatment of dyslipidemia, a major modifiable risk factor for developing
atherosclerotic cardiovascular disease (ASCVD), remains a debated and controversial …

Extracellular vesicles and exomere nanoparticles are under intense investigation as sources
of clinically relevant cargo. Here we report the discovery of a distinct extracellular …

Inhibitors of proprotein convertase subtilisin/kexin type 9 (PCSK9) reduce low-density
lipoprotein (LDL) cholesterol and are used for treatment of dyslipidemia. Current PCSK9 …

Neutrophil infiltration around lipotoxic hepatocytes is a hallmark of nonalcoholic
steatohepatitis (NASH); however, how these 2 types of cells communicate remains obscure …

Cardiovascular disease (CVD) is the leading cause of death in the United States and
worldwide. A major risk factor for this condition is increased serum low-density lipoprotein …

Optimal care for familial hypercholesterolaemia (FH) requires patient-centred management,
multidisciplinary teamwork, involvement of primary care practitioners, patient networks …

Proprotein convertase subtilisin/kexin type 9 (PCSK9) promotes degradation of low-density
lipoprotein receptor (LDLR) and plays a central role in regulating plasma levels of LDL …

Atherosclerotic cardiovascular disease (ASCVD) remains a leading cause of morbidity and
mortality despite excellent pharmacological and revascularization approaches. Low-density …

Pro-protein convertase subtilisin/kexin type 9 (PCSK9) is secreted mostly by hepatocytes
and to a lesser extent by the intestine, pancreas, kidney, adipose tissue, and vascular cells …